Lymphoma: all 5,623 studies
Page 8 of 57. Open to participants first (823), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruitingNCT04570423Phase 2
- Prognostic Nomogram of Extranodal NK/T-cell LymphomaRecruitingNCT04554511
- A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignanciesRecruitingNCT04532281Early Phase 1
- A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLRecruitingNCT04532268Early Phase 1
- A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesRecruitingNCT04532203Early Phase 1
- Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous LymphomasNot yet recruitingNCT04520529Not applicable
- The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.RecruitingNCT04514081Phase 2
- Tumor Molecular Profiling in Early Phase Clinical TrialsRecruitingNCT04510766
- Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative DiseasesRecruitingNCT04504526Early Phase 1
- The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell LymphomaRecruitingNCT04489264
- Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell LymphomaRecruitingNCT04484506Phase 2
- Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological MalignanciesRecruitingNCT04470947
- Better Leukemia Diagnostics Through AI (BELUGA)RecruitingNCT04466059
- A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory LymphomasRecruitingNCT04458389Phase 1/2
- Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by ImmunochemotherapyRecruitingNCT04442412Phase 3
- Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular TechniquesRecruitingNCT04417803Not applicable
- Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell LymphomaRecruitingNCT04414969Phase 2
- Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell LymphomasRecruitingNCT04407741Phase 1/2
- BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantRecruitingNCT04378647Phase 2
- CONFIRM: Magnetic Resonance Guided Radiation TherapyRecruitingNCT04368702Not applicable
- A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)RecruitingNCT04365036Phase 3
- Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorRecruitingNCT04337606Phase 1/2
- A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell LymphomaRecruitingNCT04332822Phase 3
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/2
- Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingNCT04301076Phase 1
- Study of CAR-T Therapy in Older PatientsRecruitingNCT04300998
- Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT04300101
- Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological MalignanciesRecruitingNCT04290000
- CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
- Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in LymphomaRecruitingNCT04263935
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingNCT04234048Phase 1
- Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin LymphomaRecruitingNCT04233294Phase 2
- Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.RecruitingNCT04223765Phase 1
- Quality of Life in Lymphoma Patients One Year Post-chemotherapyRecruitingNCT04187118
- BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid LymphomaRecruitingNCT04162353Phase 1
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
- Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell LymphomaRecruitingNCT04128072Phase 2
- MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)RecruitingNCT04110301Phase 1/2
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
- ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-LymphomaRecruitingNCT04097067Not applicable
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingNCT04094610Phase 1/2
- Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable
- Cell Free DNA in Mature B-cell LymphomaRecruitingNCT04088422
- CD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaRecruitingNCT04083495Phase 2
- Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04070040Phase 2
- Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell LymphomaRecruitingNCT04058470Phase 1/2
- Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related ComplicationsRecruitingNCT04053439
- Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With MogamulizumabRecruitingNCT04014374
- Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated BoostRecruitingNCT04006561
- A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBLRecruitingNCT03971318
- A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCLRecruitingNCT03971305
- Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern ChemoradiationNot yet recruitingNCT03969693
- Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.RecruitingNCT03964480
- Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCLRecruitingNCT03958916
- Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT03936153Phase 2
- Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/2
- REal World Data in LYmphoma and Survival in AdultsRecruitingNCT03869619
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
- CD4CAR for CD4+ Leukemia and LymphomaRecruitingNCT03829540Phase 1
- A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and LymphomaRecruitingNCT03829254Phase 1/2
- Post-Op Pain Control for Prophylactic Intramedullary Nailing.RecruitingNCT03823534Phase 3
- Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal LymphomaRecruitingNCT03746223Phase 2
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT03702309
- Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CARRecruitingNCT03676504Phase 1/2
- A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma PatientsRecruitingNCT03650933Phase 3
- PPI Versus Histamine Antagnists as Adjuvant to ChemotherapyRecruitingNCT03647072Phase 3
- Pilot Imaging Study of LeukemiaRecruitingNCT03633955Phase 1
- Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)RecruitingNCT03616782Phase 2
- Managed Access Programs for CTL019, TisagenlecleucelAvailableNCT03601442
- Effect of Needle Size in Diagnostic Yield of EBUS-TBNA in Sarcoidosis and LymphomaRecruitingNCT03573362Not applicable
- [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS LymphomaRecruitingNCT03569995Phase 2
- Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.RecruitingNCT03500133Phase 4
- Pediatric PET/MR Image RegistryRecruitingNCT03458520
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingNCT03418038Phase 2
- CD30 Targeted CAR-T in Treating CD30-Expressing LymphomasRecruitingNCT03383965Phase 1
- A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and LeukemiaRecruitingNCT03383952Phase 1
- A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell LymphomaEnrolling by invitationNCT03383406Phase 2
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingNCT03328078Phase 1/2
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- China Lymphoma Patient Registry StudyRecruitingNCT03313271
- Sample Collection and Tracking for the Developmental Therapeutics ClinicRecruitingNCT03269578
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 2
- SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03250962Phase 2
- Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by invitationNCT03226704
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
- Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)RecruitingNCT03199066
- Bergamo Lymphoid Cancer RegistryRecruitingNCT03131531
- Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IIIRecruitingNCT03117036
- Umbilical Cord Blood Transplantation From Unrelated DonorsRecruitingNCT03016806
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingNCT02974647Phase 2
- Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.RecruitingNCT02964858Not applicable
- CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)RecruitingNCT02917083Phase 1
- Institut Paoli Calmettes Lymphoma DatabaseRecruitingNCT02869542
- ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaRecruitingNCT02858258Phase 3
- Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSLRecruitingNCT02836158Phase 2/3
- Treatment for Classical Hodgkin Lymphoma in Children and AdolescentsRecruitingNCT02797717Not applicable
- PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T LymphomaRecruitingNCT02705508Phase 2
- Treatment of PCNSL With R-IDARAM and Intrathecal ImmunochemotherapyRecruitingNCT02657785Phase 2/3
- Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single InstituteRecruitingNCT02655744